Loading…

Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity

Biofilm mediated bacterial infections are the key factors in the progression of infectious diseases due to the evolution of antimicrobial resistance. Traditional therapy involving antibiotics is not adequate enough for treatment of such infections due to the increased resistance triggered by biofilm...

Full description

Saved in:
Bibliographic Details
Published in:Drug delivery and translational research 2021-02, Vol.11 (1), p.305-317
Main Authors: Anjum, Md Meraj, Patel, Krishna Kumar, Dehari, Deepa, Pandey, Nidhi, Tilak, Ragini, Agrawal, Ashish Kumar, Singh, Sanjay
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3
cites cdi_FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3
container_end_page 317
container_issue 1
container_start_page 305
container_title Drug delivery and translational research
container_volume 11
creator Anjum, Md Meraj
Patel, Krishna Kumar
Dehari, Deepa
Pandey, Nidhi
Tilak, Ragini
Agrawal, Ashish Kumar
Singh, Sanjay
description Biofilm mediated bacterial infections are the key factors in the progression of infectious diseases due to the evolution of antimicrobial resistance. Traditional therapy involving antibiotics is not adequate enough for treatment of such infections due to the increased resistance triggered by biofilm. To overcome this challenge, we developed anacardic acid (Ana) loaded solid lipid nanoparticles (SLNs), further coated with chitosan and DNase (Ana-SLNs-CH-DNase). The DNase coating was hypothesized to degrade the e-DNA, while chitosan was coated to yield positively charged SLNs with additional adhesion to biofilms. The SLNs were developed using homogenization method and further evaluated for particle size, polydispersity index, zeta potential, and entrapment efficiency. Drug excipient compatibility was confirmed by using FT-IR study, while encapsulation of Ana in SLNs was confirmed by X-ray diffraction study. The SLNs demonstrated sustained release for up to 24 h and excellent stability at room temperature for up to 3 months. The developed SLNs were found non-toxic against human immortalized keratinocyte (HaCaT) cells while demonstrated remarkably higher antimicrobial efficacy against Staphylococcus aureus . Excellent effect of the developed SLNs on minimum biofilm inhibition concentration and minimum biofilm eradication concentration further confirmed the superiority of the developed formulation strategy. A significant ( p < 0.05) reduction in biofilm thickness and biomass, as confirmed by confocal laser scanning microscopy, was observed in the case of developed SLNs in comparison with control. Cumulatively, the results suggest the enhanced efficacy of the developed formulation strategy to overcome the biofilm-mediated antimicrobial resistance. Graphical abstract
doi_str_mv 10.1007/s13346-020-00795-4
format article
fullrecord <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s13346_020_00795_4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1007_s13346_020_00795_4</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3</originalsourceid><addsrcrecordid>eNp9UMtKAzEUHUTBUvsDrvIDo3nM012pTyi6UMFduM2jTZlJhiRTmG_xZ41WXHoX98U9h3NPll0SfEUwrq8DYayockxxnsa2zIuTbEZJi3PWFs3pX88-zrNFCHucoqhI3daz7HNpQYCXRiAQRiJlBQxh7CAqiYLr0qozQ8oWrBvARyM6FZB2Hr1GGHZT54QTYgwIRq9S2RinTdejuFMehukGiZ2JLoBFYCW6fYagkHAQjd0i0w_eHRId2Gh6I7zbGOiSkGgOJk4X2ZmGLqjFb51n7_d3b6vHfP3y8LRarnNBK1rkrNww2eCalhpXrdS1TF2LNVOVYCBLXLCWQKUIpE9p2QCGlmHZNA2mgmrB5hk98iYBIXil-eBND37iBPNvh_nRYZ4c5j8O8yKB2BEU0rHdKs_3bvQ26fwP9QUFXYMF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity</title><source>Springer Nature</source><creator>Anjum, Md Meraj ; Patel, Krishna Kumar ; Dehari, Deepa ; Pandey, Nidhi ; Tilak, Ragini ; Agrawal, Ashish Kumar ; Singh, Sanjay</creator><creatorcontrib>Anjum, Md Meraj ; Patel, Krishna Kumar ; Dehari, Deepa ; Pandey, Nidhi ; Tilak, Ragini ; Agrawal, Ashish Kumar ; Singh, Sanjay</creatorcontrib><description>Biofilm mediated bacterial infections are the key factors in the progression of infectious diseases due to the evolution of antimicrobial resistance. Traditional therapy involving antibiotics is not adequate enough for treatment of such infections due to the increased resistance triggered by biofilm. To overcome this challenge, we developed anacardic acid (Ana) loaded solid lipid nanoparticles (SLNs), further coated with chitosan and DNase (Ana-SLNs-CH-DNase). The DNase coating was hypothesized to degrade the e-DNA, while chitosan was coated to yield positively charged SLNs with additional adhesion to biofilms. The SLNs were developed using homogenization method and further evaluated for particle size, polydispersity index, zeta potential, and entrapment efficiency. Drug excipient compatibility was confirmed by using FT-IR study, while encapsulation of Ana in SLNs was confirmed by X-ray diffraction study. The SLNs demonstrated sustained release for up to 24 h and excellent stability at room temperature for up to 3 months. The developed SLNs were found non-toxic against human immortalized keratinocyte (HaCaT) cells while demonstrated remarkably higher antimicrobial efficacy against Staphylococcus aureus . Excellent effect of the developed SLNs on minimum biofilm inhibition concentration and minimum biofilm eradication concentration further confirmed the superiority of the developed formulation strategy. A significant ( p &lt; 0.05) reduction in biofilm thickness and biomass, as confirmed by confocal laser scanning microscopy, was observed in the case of developed SLNs in comparison with control. Cumulatively, the results suggest the enhanced efficacy of the developed formulation strategy to overcome the biofilm-mediated antimicrobial resistance. Graphical abstract</description><identifier>ISSN: 2190-393X</identifier><identifier>EISSN: 2190-3948</identifier><identifier>DOI: 10.1007/s13346-020-00795-4</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Original Article ; Pharmaceutical Sciences/Technology</subject><ispartof>Drug delivery and translational research, 2021-02, Vol.11 (1), p.305-317</ispartof><rights>Controlled Release Society 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3</citedby><cites>FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3</cites><orcidid>0000-0002-6748-0585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Anjum, Md Meraj</creatorcontrib><creatorcontrib>Patel, Krishna Kumar</creatorcontrib><creatorcontrib>Dehari, Deepa</creatorcontrib><creatorcontrib>Pandey, Nidhi</creatorcontrib><creatorcontrib>Tilak, Ragini</creatorcontrib><creatorcontrib>Agrawal, Ashish Kumar</creatorcontrib><creatorcontrib>Singh, Sanjay</creatorcontrib><title>Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity</title><title>Drug delivery and translational research</title><addtitle>Drug Deliv. and Transl. Res</addtitle><description>Biofilm mediated bacterial infections are the key factors in the progression of infectious diseases due to the evolution of antimicrobial resistance. Traditional therapy involving antibiotics is not adequate enough for treatment of such infections due to the increased resistance triggered by biofilm. To overcome this challenge, we developed anacardic acid (Ana) loaded solid lipid nanoparticles (SLNs), further coated with chitosan and DNase (Ana-SLNs-CH-DNase). The DNase coating was hypothesized to degrade the e-DNA, while chitosan was coated to yield positively charged SLNs with additional adhesion to biofilms. The SLNs were developed using homogenization method and further evaluated for particle size, polydispersity index, zeta potential, and entrapment efficiency. Drug excipient compatibility was confirmed by using FT-IR study, while encapsulation of Ana in SLNs was confirmed by X-ray diffraction study. The SLNs demonstrated sustained release for up to 24 h and excellent stability at room temperature for up to 3 months. The developed SLNs were found non-toxic against human immortalized keratinocyte (HaCaT) cells while demonstrated remarkably higher antimicrobial efficacy against Staphylococcus aureus . Excellent effect of the developed SLNs on minimum biofilm inhibition concentration and minimum biofilm eradication concentration further confirmed the superiority of the developed formulation strategy. A significant ( p &lt; 0.05) reduction in biofilm thickness and biomass, as confirmed by confocal laser scanning microscopy, was observed in the case of developed SLNs in comparison with control. Cumulatively, the results suggest the enhanced efficacy of the developed formulation strategy to overcome the biofilm-mediated antimicrobial resistance. Graphical abstract</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Original Article</subject><subject>Pharmaceutical Sciences/Technology</subject><issn>2190-393X</issn><issn>2190-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9UMtKAzEUHUTBUvsDrvIDo3nM012pTyi6UMFduM2jTZlJhiRTmG_xZ41WXHoX98U9h3NPll0SfEUwrq8DYayockxxnsa2zIuTbEZJi3PWFs3pX88-zrNFCHucoqhI3daz7HNpQYCXRiAQRiJlBQxh7CAqiYLr0qozQ8oWrBvARyM6FZB2Hr1GGHZT54QTYgwIRq9S2RinTdejuFMehukGiZ2JLoBFYCW6fYagkHAQjd0i0w_eHRId2Gh6I7zbGOiSkGgOJk4X2ZmGLqjFb51n7_d3b6vHfP3y8LRarnNBK1rkrNww2eCalhpXrdS1TF2LNVOVYCBLXLCWQKUIpE9p2QCGlmHZNA2mgmrB5hk98iYBIXil-eBND37iBPNvh_nRYZ4c5j8O8yKB2BEU0rHdKs_3bvQ26fwP9QUFXYMF</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Anjum, Md Meraj</creator><creator>Patel, Krishna Kumar</creator><creator>Dehari, Deepa</creator><creator>Pandey, Nidhi</creator><creator>Tilak, Ragini</creator><creator>Agrawal, Ashish Kumar</creator><creator>Singh, Sanjay</creator><general>Springer US</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-6748-0585</orcidid></search><sort><creationdate>20210201</creationdate><title>Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity</title><author>Anjum, Md Meraj ; Patel, Krishna Kumar ; Dehari, Deepa ; Pandey, Nidhi ; Tilak, Ragini ; Agrawal, Ashish Kumar ; Singh, Sanjay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Original Article</topic><topic>Pharmaceutical Sciences/Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anjum, Md Meraj</creatorcontrib><creatorcontrib>Patel, Krishna Kumar</creatorcontrib><creatorcontrib>Dehari, Deepa</creatorcontrib><creatorcontrib>Pandey, Nidhi</creatorcontrib><creatorcontrib>Tilak, Ragini</creatorcontrib><creatorcontrib>Agrawal, Ashish Kumar</creatorcontrib><creatorcontrib>Singh, Sanjay</creatorcontrib><collection>CrossRef</collection><jtitle>Drug delivery and translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anjum, Md Meraj</au><au>Patel, Krishna Kumar</au><au>Dehari, Deepa</au><au>Pandey, Nidhi</au><au>Tilak, Ragini</au><au>Agrawal, Ashish Kumar</au><au>Singh, Sanjay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity</atitle><jtitle>Drug delivery and translational research</jtitle><stitle>Drug Deliv. and Transl. Res</stitle><date>2021-02-01</date><risdate>2021</risdate><volume>11</volume><issue>1</issue><spage>305</spage><epage>317</epage><pages>305-317</pages><issn>2190-393X</issn><eissn>2190-3948</eissn><abstract>Biofilm mediated bacterial infections are the key factors in the progression of infectious diseases due to the evolution of antimicrobial resistance. Traditional therapy involving antibiotics is not adequate enough for treatment of such infections due to the increased resistance triggered by biofilm. To overcome this challenge, we developed anacardic acid (Ana) loaded solid lipid nanoparticles (SLNs), further coated with chitosan and DNase (Ana-SLNs-CH-DNase). The DNase coating was hypothesized to degrade the e-DNA, while chitosan was coated to yield positively charged SLNs with additional adhesion to biofilms. The SLNs were developed using homogenization method and further evaluated for particle size, polydispersity index, zeta potential, and entrapment efficiency. Drug excipient compatibility was confirmed by using FT-IR study, while encapsulation of Ana in SLNs was confirmed by X-ray diffraction study. The SLNs demonstrated sustained release for up to 24 h and excellent stability at room temperature for up to 3 months. The developed SLNs were found non-toxic against human immortalized keratinocyte (HaCaT) cells while demonstrated remarkably higher antimicrobial efficacy against Staphylococcus aureus . Excellent effect of the developed SLNs on minimum biofilm inhibition concentration and minimum biofilm eradication concentration further confirmed the superiority of the developed formulation strategy. A significant ( p &lt; 0.05) reduction in biofilm thickness and biomass, as confirmed by confocal laser scanning microscopy, was observed in the case of developed SLNs in comparison with control. Cumulatively, the results suggest the enhanced efficacy of the developed formulation strategy to overcome the biofilm-mediated antimicrobial resistance. Graphical abstract</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s13346-020-00795-4</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6748-0585</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2190-393X
ispartof Drug delivery and translational research, 2021-02, Vol.11 (1), p.305-317
issn 2190-393X
2190-3948
language eng
recordid cdi_crossref_primary_10_1007_s13346_020_00795_4
source Springer Nature
subjects Biomedical and Life Sciences
Biomedicine
Original Article
Pharmaceutical Sciences/Technology
title Anacardic acid encapsulated solid lipid nanoparticles for Staphylococcus aureus biofilm therapy: chitosan and DNase coating improves antimicrobial activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A49%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anacardic%20acid%20encapsulated%20solid%20lipid%20nanoparticles%20for%20Staphylococcus%20aureus%20biofilm%20therapy:%20chitosan%20and%20DNase%20coating%20improves%20antimicrobial%20activity&rft.jtitle=Drug%20delivery%20and%20translational%20research&rft.au=Anjum,%20Md%20Meraj&rft.date=2021-02-01&rft.volume=11&rft.issue=1&rft.spage=305&rft.epage=317&rft.pages=305-317&rft.issn=2190-393X&rft.eissn=2190-3948&rft_id=info:doi/10.1007/s13346-020-00795-4&rft_dat=%3Ccrossref_sprin%3E10_1007_s13346_020_00795_4%3C/crossref_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2624-35b3d80725f069df7d25f90f3e6c3ad504391a6e1aaca258a0a930d88802c2fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true